Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Rating of “Hold” from Analysts

Elanco Animal Health Incorporated (NYSE:ELANGet Rating) has been assigned an average rating of “Hold” from the eight research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $17.83.

A number of research firms have issued reports on ELAN. Morgan Stanley decreased their target price on Elanco Animal Health from $21.00 to $20.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 15th. JPMorgan Chase & Co. lowered their price target on Elanco Animal Health from $24.00 to $20.00 and set a “neutral” rating on the stock in a research report on Monday, October 17th. Piper Sandler decreased their price objective on Elanco Animal Health from $21.00 to $15.00 and set a “neutral” rating on the stock in a report on Monday, November 14th. Barclays decreased their price objective on Elanco Animal Health from $32.00 to $18.00 and set an “equal weight” rating on the stock in a report on Monday, September 12th. Finally, The Goldman Sachs Group decreased their price objective on Elanco Animal Health from $19.00 to $12.00 and set a “sell” rating on the stock in a report on Wednesday, November 9th.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $12.21 on Thursday. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.96 and a quick ratio of 1.12. The business has a fifty day simple moving average of $12.77 and a two-hundred day simple moving average of $17.49. Elanco Animal Health has a 1 year low of $11.34 and a 1 year high of $31.98. The company has a market capitalization of $5.79 billion, a P/E ratio of -50.87, a P/E/G ratio of 6.14 and a beta of 0.92.

Insider Transactions at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons acquired 30,000 shares of the company’s stock in a transaction on Friday, September 9th. The stock was acquired at an average price of $14.54 per share, with a total value of $436,200.00. Following the acquisition, the chief executive officer now directly owns 30,000 shares of the company’s stock, valued at $436,200. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director R David Hoover bought 20,000 shares of the stock in a transaction on Friday, September 9th. The stock was bought at an average cost of $15.18 per share, for a total transaction of $303,600.00. Following the completion of the purchase, the director now directly owns 145,000 shares in the company, valued at $2,201,100. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jeffrey N. Simmons acquired 30,000 shares of the stock in a transaction dated Friday, September 9th. The shares were bought at an average price of $14.54 per share, with a total value of $436,200.00. Following the completion of the purchase, the chief executive officer now directly owns 30,000 shares of the company’s stock, valued at approximately $436,200. The disclosure for this purchase can be found here. Insiders purchased 64,200 shares of company stock worth $938,930 in the last three months. Corporate insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Advisor Group Holdings Inc. lifted its holdings in shares of Elanco Animal Health by 13.3% in the 1st quarter. Advisor Group Holdings Inc. now owns 108,697 shares of the company’s stock worth $2,757,000 after acquiring an additional 12,761 shares during the last quarter. KBC Group NV boosted its holdings in shares of Elanco Animal Health by 13.5% in the 2nd quarter. KBC Group NV now owns 100,780 shares of the company’s stock valued at $1,978,000 after buying an additional 11,949 shares in the last quarter. AGF Investments LLC boosted its stake in Elanco Animal Health by 19.3% during the 1st quarter. AGF Investments LLC now owns 31,582 shares of the company’s stock worth $824,000 after purchasing an additional 5,116 shares during the period. Geneos Wealth Management Inc. lifted its stake in shares of Elanco Animal Health by 9.3% in the 2nd quarter. Geneos Wealth Management Inc. now owns 12,980 shares of the company’s stock worth $267,000 after acquiring an additional 1,103 shares during the period. Finally, Sciencast Management LP increased its holdings in shares of Elanco Animal Health by 3.9% in the 2nd quarter. Sciencast Management LP now owns 27,560 shares of the company’s stock valued at $559,000 after purchasing an additional 1,030 shares in the last quarter. Hedge funds and other institutional investors own 98.15% of the company’s stock.

Elanco Animal Health Company Profile

(Get Rating)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

See Also

Analyst Recommendations for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.